GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
GSK (GSK) stock crumbled Friday after the Food and Drug Administration granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.
The agency signed off on several combinations using Blenrep to treat multiple myeloma patients who'... [2123 chars]